During teriparatide treatment, rheumatoid arthritis patients had greater femoral neck BMD increases than postmenopausal osteoporosis patients, 4.7% versus 0.7%.
In plain wordsDuring teriparatide treatment, rheumatoid arthritis patients had larger femoral neck BMD increases than postmenopausal osteoporosis patients.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- IncreaseFemoral neck BMD response
- Study
n = 132
- Comparator
- Postmenopausal osteoporosis patients receiving teriparatide
- Outcome group
- Bone and joint · Musculoskeletal
Measurements
- Femoral neck BMD increase at 18 months
- 4.7%
- rheumatoid arthritis
- Femoral neck BMD increase at 18 months
- 0.7%
- postmenopausal osteoporosis
Source sentences
Femoral neck (FN) bone mineral density (BMD) increase at 18 months was significantly greater in RA compared to Porosis (4.7 vs. 0.7 %, P = 0.038), whereas it was 9.7 versus 7.9 % (P = 0.736) in the lumbar spine (LS).
2 context sentences(design, population, supporting numbers)
The aim of this study was to evaluate the effects of 18-month administration of daily teriparatide (TPTD) in osteoporosis patients with rheumatoid arthritis (RA) by comparing that of postmenopausal osteoporosis patients (Porosis).
The effects of TPTD were examined between RA (n = 70; age 68.4 years; disease activity score assessing 28 joints with CRP [DAS28-CRP] 2.8; rheumatoid factor [RF] positivity 75.5 %) with 77.1 % of prior bisphosphonate (BP), 84.3 % of oral prednisolone (PSL) (4.4 mg/day at baseline), 25.7 % of biologi…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).